Journal of Molecular and Cellular Cardiology
Volume 42, Issue 2 , Pages 280-282 , February 2007

eNOS phosphorylation: A pivotal molecular switch in vasodilation and cardioprotection?

  • Rakesh C. Kukreja

      Affiliations

    • Corresponding Author InformationCorresponding author. Eric Lipman Chair of Cardiology, Division of Cardiology, Box 980281, Virginia Commonwealth University, 1101 East Mashall Street, Room 7-046, Richmond, VA 23298, USA. Tel.: +1 804 828 0389; fax: +1 804 828 8700.
  • ,
  • Lei Xi

Received 22 October 2006 ,Accepted 23 October 2006.

References 

  1. Lowenstein CJ, Michel T. What's in a name? eNOS and anaphylactic shock. J. Clin. Invest. 2006;116(8):2075–2078
  2. Kone BC, Kuncewicz T, Zhang W, Yu ZY. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am. J. Physiol.: Renal. Physiol. 2003;285(2):F178–F190
  3. Michel T, Li GK, Busconi L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 1993;90(13):6252–6256
  4. Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ. Res. 1996;79(5):984–991
  5. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399(6736):597–601
  6. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601–605
  7. Gallis B, Corthals GL, Goodlett DR, Ueba H, Kim F, Presnell SR, et al. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J. Biol. Chem. 1999;274(42):30101–30108
  8. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 1999;9(15):845–848
  9. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443(3):285–289
  10. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, Jo H. Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic. Biol. Med. 2006;41(1):144–153
  11. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?. J. Pharmacol. Exp. Ther. 2001;299(3):818–824
  12. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol. 2006;[July 12; electronic publication ahead of print]
  13. Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, Guo Y, et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ. Res. 1997;81(6):1094–1107
  14. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J. Biol. Chem. 2005;280(13):12944–12955
  15. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 2006;40(1):16–23
  16. Tosaki A, Maulik N, Elliott GT, Blasig IE, Engelman RM, Das DK. Preconditioning of rat heart with monophosphoryl lipid A: a role for nitric oxide. J. Pharmacol. Exp. Ther. 1998;285(3):1274–1279
  17. Xi L, Kukreja RC. Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction. Toxicology. 2000;155(1–3):37–44
  18. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res. 2004;95(3):230–232
  19. Zhang J, Baines CP, Zong C, Cardwell EM, Wang G, Vondriska TM, et al. Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection. Am. J. Physiol.: Heart Circ. Physiol. 2005;288(2):H954–H961
  20. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc. Res. 2006;72(1):152–162
  21. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia–reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002;105(12):1497–1502
  22. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia–reperfusion injury. Cardiovasc. Res. 2005;65(2):345–355
  23. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J. Cardiovasc. Pharmacol. 2004;44(3):348–355
  24. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ. Res. 2005;96(11):1185–1192
  25. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. 2003;41(3):508–515
  26. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J. Mol. Cell. Cardiol. 2003;35(2):185–193
  27. Kukreja RC. Synergistic effects of atorvastatin and sildenafil in cardioprotection—Role of NO. Cardiovasc. Drugs Ther. 2006;20(1):5–8
  28. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, et al. Enhanced cardioprotection against ischemia–reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc. Drugs Ther. 2006;20(1):27–36
  29. Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res. Cardiol. 2006;[Aug 14; electronic publication ahead of print]
  30. Musicki B, Kramer MF, Becker RE, Burnett AL. Age-related changes in phosphorylation of endothelial nitric oxide synthase in the rat penis. J. Sex Med. 2005;2(3):347–355
  31. Bell RM, Yellon DM. The contribution of endothelial nitric oxide synthase to early ischaemic preconditioning: the lowering of the preconditioning threshold. An investigation in eNOS knockout mice. Cardiovasc. Res. 2001;52(2):274–280
  32. Cauwels A, Janssen B, Buys E, Sips P, Brouckaert P. Anaphylactic shock depends on PI3K and eNOS-derived NO. J. Clin. Invest. 2006;116(8):2244–2251
  33. Connelly L, Madhani M, Hobbs AJ. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived NO in vivo. J. Biol. Chem. 2005;280(11):10040–10046
  34. Hoffmann J, Haendeler J, Aicher A, Rossig L, Vasa M, Zeiher AM, et al. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ. Res. 2001;89(8):709–715
  35. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 2003;9(11):1370–1376

PII: S0022-2828(06)00975-8

doi: 10.1016/j.yjmcc.2006.10.011

Journal of Molecular and Cellular Cardiology
Volume 42, Issue 2 , Pages 280-282 , February 2007